Senda Biosciences, Inc. is committed to bringing life-changing treatments to patients by harnessing millennia of evolution to program human cells both within and to the cell. Senda’s proprietary platform is the first to leverage a universal chemical routing code of natural nanoparticles that enable cross- kingdom intercellular communication. This platform unlocks comprehensive programming of medicines for the first time, allowing Senda to develop a new class of SendRNATM medicines focused initially on powering new frontiers in immunology mRNA-based therapies, with future applications employing other information molecules, including siRNA, gene editors, proteins, and peptides. Headquartered in Cambridge, Massachusetts, Senda was founded by Flagship Pioneering. For more information, visit www.sendabiosciences.com.